Sector: Health Care
Director information for REPLIGEN CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Carrie Eglinton Manner | President and Chief Executive Officer; Director | 52 | ["Public Company Board/CEO", "Risk Oversight", "Finance & Capital Markets", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing", "Over 30 years of leadership experience across advanced diagnostics, clinical laboratory services and global healthcare technology", "Served as President and CEO and a director of OraSure Technologies, Inc. since 2022", "Senior Vice President, Advanced & General Diagnostics and Clinical Solutions at Quest Diagnostics from 2017 to 2022", "Oversaw value creation across company\u2019s $10 billion clinical portfolio at Quest", "Spent two decades at GE Healthcare with expertise in healthcare, commercial, operational and regulated manufacturing", "Served as President and CEO of four distinct global businesses"] | ["Audit"] | 2026 |
| Glenn P. Muir | Retired Chief Financial Officer and Executive Vice President; Director | 67 | ["Public Company Board/CEO", "Risk Oversight", "Finance & Capital Markets", "Manufacturing & Global Operations", "Over 30 years of experience in the medical device and diagnostics industry", "26 years with Hologic, Inc. as CFO and Executive Vice President", "Experience in steering company evolution from venture-backed to publicly-traded", "Former Vice President of Finance at Metallon Engineered Materials Co.", "Senior Auditor with Arthur Andersen & Co.", "Certified Public Accountant", "B.A. from the University of Massachusetts, Amherst", "M.S. in Taxation from Bentley University", "M.B.A. from Harvard University", "Experience with strategic acquisitions and financial operations for a global organization"] | ["Audit", "Compensation"] | 2026 |
| Karen A. Dawes | Director; President of Knowledgeable Decisions, LLC | 74 | ["Public Company Board/CEO", "Risk Oversight", "Manufacturing & Global Operations", "Commercial Sales & Marketing", "Former Lead Independent Director and Chairperson of the Board", "Senior Vice President and U.S. Business Group Head for Bayer Corporation\u2019s U.S. Pharmaceuticals Group", "Senior Vice President, Global Strategic Marketing, at Wyeth LLC", "Vice President, Commercial Operations for Genetics Institute, Inc.", "Held marketing positions at Pfizer, Inc.", "Board member of Barinthus Bio, JPA Health, and Medicines 360"] | ["Audit"] | 2026 |
| Konstantin Konstantinov, Ph.D. | Chief Technology Officer; Director | 68 | ["Risk Oversight", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Chief Technology Officer at Ring Therapeutics", "Operating Partner at Flagship Pioneering", "Former Chief Technology Officer at Codiak BioSciences", "Experience at Sanofi's Boston hub in bioprocess and technology development", "Former Head of Process Sciences at Bayer", "Published 60 peer-reviewed papers", "More than 15 patents and patent applications", "Experience in development and commercialization of biotechnology products"] | ["Nominating & Corporate Governance"] | 2026 |
| Margaret A. Pax | Former Vice President, Strategy and Innovation; Director | 66 | ["Public Company Board/CEO", "Risk Oversight", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing", "Over 30 years of experience leading the development and execution of growth strategies for global life sciences companies", "Vice President, Strategy and Innovation for Thermo Fisher Clinical Services from 2016 to 2020", "Senior Director, Corporate Development & Strategy at Thermo Fisher from 2013 to 2016", "Senior Director, Portable Analytical Instrumentation for Thermo Fisher from 2012 to 2013", "Held senior leadership roles at Philips Healthcare from 1989 to 2000", "Vice President, Business and Clinical Development with Microchips Biomedical from 2006 to 2011", "Independent board director at Alimera Sciences from 2023 to 2024", "Independent director of Jellagen", "Experience with the U.S. subsidiary of BioPorto A/S from 2021 to 2024", "B.A. from the College of Holy Cross", "M.B.A. from Harvard Business School"] | ["Compensation"] | 2026 |
| Martin D. Madaus, D.V.M., Ph.D. | Chair (2) Senior Operating Executive | 66 | [] | ["Audit", "Compensation", "Nominating & Corporate Governance"] | 2026 |
| Martin D. Madaus, Ph.D. | Chair of the Board | ["over 25 years of industry experience", "five years as Chairman, President and CEO of Millipore Corporation", "senior operating executive at The Carlyle Group since 2019", "Chairman and CEO at Ortho-Clinical Diagnostics from 2014 to 2019", "President and CEO, N.A. of Roche Diagnostics Corp. from 2000 to 2004", "held sales, marketing and product management roles at Boehringer Mannheim Corporation from 1989 to 1996"] | [] | 2026 | |
| Martin Madaus, D.V.M., Ph.D. | Director, Chair of the Board | 66 | ["Public Company Board/CEO", "Risk Oversight", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing"] | [] | 2026 |
| Nicolas M. Barthelemy | Senior Advisor, Warburg Pincus; Director | 60 | ["Public Company Board/CEO", "Risk Oversight", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing", "over 30 years of industry experience", "served as President and CEO of bioTheranostics", "served as President, Global Commercial Operations at Life Technologies", "Vice President, Manufacturing and General Manager at Biogen", "Senior Project Engineer, Vaccine Technology at Merck & Co., Inc.", "Senior Advisor at Warburg Pincus since 2020", "M.S. in Chemical Engineering from the University of California, Berkeley", "engineering degree from Ecole Sup\u00e9rieure de Physique et Chimie Industrielles, Paris", "extensive experience in the bioprocessing field", "large scale biologics manufacturing", "commercialization of consumables used in bioprocessing", "strategy and merger and acquisitions"] | ["Nominating & Corporate Governance"] | 2026 |
| Olivier Loeillot | President and Chief Executive Officer, Director; President and CEO | 56 | ["Public Company Board/CEO", "Risk Oversight", "Finance & Capital Markets", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing", "CEO of Ascensus Specialties", "12 years with Cytiva", "12 years with Lonza", "Master's degree in Chemistry", "MBA from CESMA Business School"] | [] | 2026 |
| Rohin Mhatre, Ph.D. | Executive Vice President and Chief Technical Operations Officer; Director | 61 | ["Risk Oversight", "Finance & Capital Markets", "Manufacturing & Global Operations", "Commercial Sales & Marketing", "30 years of relevant experience", "Senior Vice President, Product and Technology Development at Biogen (2017-2023)", "Vice President of Biopharmaceutical Development at Biogen", "Led a team responsible for cell line, cell culture, purification and device development", "Technical expertise in analytical development and technical services", "Ph.D. in Chemistry from Northeastern University"] | ["Audit"] | 2026 |
